Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503768 | 0.91 | USP2 (0.35) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL16757262 | 0.88 | GRIN2B (0.35) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL25297924 | 0.87 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL1950040 | 0.87 | CYP4F2 (0.40) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL20437959 | 0.86 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL31527365 | 0.86 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL444048 | 0.86 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL19614479 | 0.85 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL19614453 | 0.85 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL15924562 | 0.85 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKJAK3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308101-A1 | METHODS OF TREATING FIBROMYALGIA | APTINYX INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-2951182-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10441572-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180244680-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180215767-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215767-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215767-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9828384-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828384-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828384-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2014120784-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSK 4114/4885 |
| US-20180244680-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSK 4114/4885 |
| US-20210308101-A1 | METHODS OF TREATING FIBROMYALGIA | LPXN, LPAR5, INA | GRIN2B 415/4885GRIN2C 449/4885CTSK 1232/4885 |
| US-20180215767-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSK 4114/4885 |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSK 4114/4885 |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | GRIN2B 3/4885GRIN2C 6/4885CTSK 4565/4885 |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSK 4114/4885 |
| US-10441572-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSK 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.